CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS

22 Oct 2026 0 comments

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

Source: NeurologyLive Published 21 Oct 2026 Imported 22 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment